Aarti Drugs Limited has confirmed the incorporation of a new wholly-owned step-down subsidiary in Chile, named Tripharma Chile SpA. This new entity is a subsidiary of Aarti’s existing Chilean holding company, Pinnacle Chile SpA. Tripharma Chile SpA was incorporated on February 27, 2026, with an initial capital contribution of Chilean Peso 10,00,000. Its primary business focus will be the marketing of formulation drugs within the Chilean market.
Formation of Overseas Step-Down Subsidiary
Aarti Drugs Limited has announced the establishment of a new overseas subsidiary, Tripharma Chile SpA, further expanding its international footprint. This entity is structured as a wholly owned subsidiary of Pinnacle Chile SpA, which is itself a subsidiary of Aarti Drugs Limited, making Tripharma Chile SpA a step-down subsidiary of the listed entity.
Key Details of Tripharma Chile SpA
The necessary incorporation formalities were completed in Chile, with the registration finalized on February 27, 2026. The subsidiary’s primary industry classification is the Pharmaceutical Industry. Its core business involves marketing formulation drugs and participating in tender and private markets within Chile, aligning with the overall business strategy of its holding companies.
Investment and Ownership Structure
The consideration paid for the subscription was Cash. The initial investment involved a Share Capital Contribution equivalent to Chilean Peso 10,00,000 (representing 10,00,000 shares). Ownership is consolidated, as 100% of the share capital in the incorporated company will be held by Pinnacle Chile SpA, a subsidiary of Aarti Drugs Limited.
Source: BSE
